Specifically, inhibiting PRDX5 can suppress DTP cell proliferation in culture, hinder CRPC progression in animal models, and stabilize PSA progression and metastatic lesions in patients, indicating that PRDX5 could be a therapeutic target for treatment‐resistant prostate cancer [74]. Here, PRDX5 is linked to prostate cancer.